Details
Stereochemistry | ACHIRAL |
Molecular Formula | 2Na.O3S2.5H2O |
Molecular Weight | 248.184 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.O.O.[Na+].[Na+].[O-]S([S-])(=O)=O
InChI
InChIKey=PODWXQQNRWNDGD-UHFFFAOYSA-L
InChI=1S/2Na.H2O3S2.5H2O/c;;1-5(2,3)4;;;;;/h;;(H2,1,2,3,4);5*1H2/q2*+1;;;;;;/p-2
Sodium thiosulfate (sodium thiosulphate/STS) is a chemical and medication. As a medication, it is used in combination with sodium nitrite under the trade name to NITHIODOTE treat cyanide poisoning. The primary route of endogenous cyanide detoxification is by enzymatic transulfuration to thiocyanate (SCN- ), which is relatively nontoxic and readily excreted in the urine. Sodium thiosulfate is thought to serve as a sulfur donor in the reaction catalyzed by the enzyme rhodanese, thus enhancing the endogenous detoxification of cyanide. In addition, Sodium thiosulfate is used in calciphylaxis in hemodialysis patients with end-stage kidney disease. Calciphylaxis is vasculopathy characterized by ischemia and painful skin necrosis due to calcification and intimal fibroplasia of thrombosis of the panicular arterioles. Sodium thiosulfate is used as treatment due to its antioxidant activity and as a chelating. Sodium thiosulfate renders renal protection by modulating the mitochondrial KATP channel for preventing urolithiasis. Moreover, STS was assumed to play a vital role in on ischemia reperfusion injury (IR). The effectiveness of STS as a cardioprotective agent was attributed to the reduction of apoptosis by binding to the active site of caspase-3 in silico, which was substantiated by the reduced expression of caspase-3 and poly ADP ribose polymerase levels.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P42574 Gene ID: 836.0 Gene Symbol: CASP3 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/28965151 |
|||
Target ID: Q15842 Gene ID: 3764.0 Gene Symbol: KCNJ8 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/26742969 |
|||
Target ID: Q14654 Gene ID: 3767.0 Gene Symbol: KCNJ11 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/26742969 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | NITHIODOTE Approved UseSodium nitrite and sodium thiosulfate are indicated for sequential use for treatment of acute cyanide poisoning that is judged to be lifethreatening. Use with caution if the diagnosis of cyanide poisoning is uncertain. Launch Date2011 |
|||
Palliative | Unknown Approved UseUnknown |
|||
Preventing | Unknown Approved UseUnknown |
Sample Use Guides
acute cyanide intoxication: Adults: 1.) Sodium Nitrite -10 mL of a 3% solution (300 mg) of sodium nitrite at the rate of 2.5 to 5 mL/minute 2.) Sodium Thiosulfate - 50 mL of a 25% solution (12.5 g) of a sodium thiosulfate solution immediately following administration of sodium nitrite.
Children: 1.) Sodium Nitrite -0.2 mL/kg of a 3% solution (6 mg/kg or 6-8 mL/m2 BSA) of sodium nitrite at the rate of 2.5 to 5 mL/minute not to exceed 10 mL (300 mg) 2.) Sodium Thiosulfate - 1 mL/kg of body weight using a 25% solution (250 mg/kg or approximately 30-40 mL/m2 of BSA) not to exceed 50 mL (12.5 g) total dose immediately following administration of sodium nitrite.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28965151
There were investigated the effectiveness of Sodium thiosulfate (STS) as a cardioprotective agent is attributed to the reduction of apoptosis by binding to the active site of caspase-3 in silico, which was substantiated by the reduced expression of caspase-3 and poly ADP ribose polymerase levels. STS of 1 mM recovered H9C2 cells from glucose oxidase/catalase-induced apoptosis. The isolated rat heart treated with STS prior to reperfusion injury (IR) injury improved its hemodynamics and reduced the infarct size to 9%. An in silico docking analysis revealed higher binding affinity of STS for caspase-3 with a binding energy of - 60.523 kcal/mol for the complex.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EPA PESTICIDE CODE |
80104
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
4.2
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
||
|
FDA ORPHAN DRUG |
244207
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
||
|
FDA ORPHAN DRUG |
322410
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
||
|
FDA ORPHAN DRUG |
239207
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/14/1414
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
||
|
FDA ORPHAN DRUG |
479415
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
||
|
FDA ORPHAN DRUG |
9585
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
||
|
FDA ORPHAN DRUG |
381912
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
||
|
FDA ORPHAN DRUG |
450114
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
||
|
FDA ORPHAN DRUG |
177303
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
13.1
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
||
|
FDA ORPHAN DRUG |
225606
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
||
|
FDA ORPHAN DRUG |
352611
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
||
|
FDA ORPHAN DRUG |
233306
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
||
|
FDA ORPHAN DRUG |
353311
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
||
|
FDA ORPHAN DRUG |
232506
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
||
|
FDA ORPHAN DRUG |
356511
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
||
|
FDA ORPHAN DRUG |
335311
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
||
|
NCI_THESAURUS |
C26170
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
||
|
CFR |
21 CFR 184.1807
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB22204
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
PRIMARY | |||
|
32150
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
PRIMARY | |||
|
DTXSID6044197
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
PRIMARY | |||
|
SODIUM THIOSULFATE
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
PRIMARY | |||
|
m10091
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
PRIMARY | Merck Index | ||
|
61475
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
PRIMARY | |||
|
10102-17-7
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
PRIMARY | |||
|
1615107
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
PRIMARY | |||
|
36726
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
PRIMARY | RxNorm | ||
|
45624
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
PRIMARY | |||
|
SODIUM THIOSULFATE
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
PRIMARY | Description: Transparent, colourless crystals; odourless. Solubility: Very soluble in water; practically insoluble in ethanol (~750 g/l) TS. Category: Antidote. Storage: Sodium thiosulfate should be kept in a tightly closed container. Additional information: Sodium thiosulfate effloresces in dry air at temperatures exceeding 33?C and dissolves in its water of crystallization at about 49?C. Definition: Sodium thiosulfate contains not less than 99.0% and not more than 101.0% of Na2S2O3,5H2O. | ||
|
CHEMBL1208642
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
PRIMARY | |||
|
HX1032V43M
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
PRIMARY | |||
|
DBSALT002504
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
PRIMARY | |||
|
C1230
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
PRIMARY | |||
|
HX1032V43M
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
PRIMARY | |||
|
4518
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
PRIMARY | |||
|
C017717
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
PRIMARY | |||
|
SUB15332MIG
Created by
admin on Fri Dec 15 15:57:04 GMT 2023 , Edited by admin on Fri Dec 15 15:57:04 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD